IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) have recently announced a resolution of all pending legal disputes and the establishment of long-term global clinical and commercial partnerships. Under this agreement, customers can now utilize software, data, technology, and service offerings from both companies in a more simplified and efficient manner.
In the commercial arena, the companies have established master data and software third-party access (TPA) agreements that allow IQVIA or Veeva data to be used with each other’s software or services in customer instances. This includes using IQVIA data in Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI. Additionally, IQVIA has joined Veeva’s technology, AI, and services partner programs to support customer integrations between Veeva software and IQVIA analytics, IQVIA information management, IQVIA agentic AI, and IQVIA commercial orchestration offerings.
In the clinical realm, IQVIA has joined Veeva’s CRO Clinical Data Partner Program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC. Customers will benefit from IQVIA’s clinical data management, clinical technology solutions, and EDC programming expertise with Veeva software to accelerate database builds, study locks, and data delivery.
These partnerships are expected to bring significant value to shared customers, with the potential to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients.
This announcement comes as a significant development, signaling a new era of collaboration and mutual benefit for both companies and their respective customer bases. Following these announcements, the company's shares moved 2.05%, and are now trading at a price of $280.61. For the full picture, make sure to review VEEVA SYSTEMS INC's 8-K report.
